Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key

Executive Summary

Eli Lilly's Olumiant (baricitinib) has won a green light from the European Medicines Agency's CHMP, for treating rheumatoid arthritis. It has advantages over future rival and fellow JAK inhibitor Xeljanz, but pricing will be key for competing against more established treatments.

Advertisement

Related Content

Lilly/Incyte's JAK Inhibitor Baricitinib Poised For FDA Approval After All
Lilly Hopes To Revitalize Its Cancer Brand With 'Foundational' Agents
Keeping Track: US FDA Shoots Down Lilly's Baricitinib, Approves Neurocrine's Ingrezza
Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA
10 Approvals To Watch For In Early 2017
Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth
4Q Pharma Results Preview, Part 2: Pfizer, Lilly, Roche, AstraZeneca, Merck, Amgen, Novo
Pfizer's Xeljanz Set To Lag Lilly's Olumiant In Europe Following Past Rebuffs
Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097890

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel